Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
First Claim
Patent Images
1. A method of treating a neoplasia in a subject in need thereof by inhibiting the growth associated therewith, said method comprising treating the subject with a therapeutically-effective amount of a compound of Formula II ##STR4## wherein R4 is C1-6 -haloalkyl;
- wherein R5 is hydrido; and
wherein R6 is phenyl optionally substituted at a substitutable position with one or more radicals selected from the group consisting of halo, C1-6 -alkylthio, C1-6 -alkylsulfonyl, cyano, nitro, C1-6 -haloalkyl, C1-6 -alkyl, hydroxyl, C2-6 -alkenyl, C1-6 -hydroxyalkyl, carboxyl, C3-6 -cycloalkyl, C1-6 -alkylamino, di-C1-6 -alkylamino, C1-6 -alkoxycarbonyl, aminocarbonyl, C1-6 -alkoxy, C1-6 -haloalkoxy, sulfamyl, five or six membered heterocyclic and amino;
or a pharmaceutically-acceptable salt or derivative thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating neoplasia. In particular, the invention describes the method of preventing and treating epithelial cell neoplasia in a subject, said method comprising treating the subject with a therapeutically-effective amount of a compound of Formula I. ##STR1## wherein A, R2 and R3 are as described in the specification.
-
Citations
15 Claims
-
1. A method of treating a neoplasia in a subject in need thereof by inhibiting the growth associated therewith, said method comprising treating the subject with a therapeutically-effective amount of a compound of Formula II ##STR4## wherein R4 is C1-6 -haloalkyl;
- wherein R5 is hydrido; and
wherein R6 is phenyl optionally substituted at a substitutable position with one or more radicals selected from the group consisting of halo, C1-6 -alkylthio, C1-6 -alkylsulfonyl, cyano, nitro, C1-6 -haloalkyl, C1-6 -alkyl, hydroxyl, C2-6 -alkenyl, C1-6 -hydroxyalkyl, carboxyl, C3-6 -cycloalkyl, C1-6 -alkylamino, di-C1-6 -alkylamino, C1-6 -alkoxycarbonyl, aminocarbonyl, C1-6 -alkoxy, C1-6 -haloalkoxy, sulfamyl, five or six membered heterocyclic and amino;
or a pharmaceutically-acceptable salt or derivative thereof. - View Dependent Claims (4, 5, 6, 7, 8, 14)
- wherein R5 is hydrido; and
-
2. A method of inhibiting or delaying the onset of a neoplasia selected from the group consisting of adenomatous polyps, gastrointestinal cancer, liver cancer, bladder cancer, cervical cancer, prostate cancer, lung cancer, breast cancer and skin cancer, in a subject in need of such inhibition or delay, the method comprising treating said subject with a therapeutically-effective amount of a compound of Formula II ##STR5## wherein R4 is C1-6 -haloalkyl;
- wherein R5 is hydrido; and
wherein R6 is phenyl optionally substituted at a substitutable position with one or more radicals selected from the group consisting of halo, C1-6 -alkylthio, C1-6 -alkylsulfonyl, cyano, nitro, C1-6 -haloalkyl, C1-6 -alkyl, hydroxyl, C2-6 -alkenyl, C1-6 -hydroxyalkyl, carboxyl, C3-6 -cycloalkyl, C1-6 -alkylamino, di-C1-6 -alkylamino, C1-6 -alkoxycarbonyl, aminocarbonyl, C1-6 -alkoxy, C1-6 -haloalkoxy, sulfamyl, five or six membered heterocyclic and amino;
or a pharmaceutically-acceptable salt or derivative thereof. - View Dependent Claims (9, 10, 11, 12, 15)
- wherein R5 is hydrido; and
-
3. A method of treating a subject suffering from a neoplastic disease state with a conjunctive therapy, said method comprising treating the subject with a therapeutically-effective amount of a compound of Formula II ##STR6## wherein R4 is C1-6 -haloalkyl;
- wherein R5 is hydrido; and
wherein R6 is phenyl optionally substituted at a substitutable position with one or more radicals selected from the group consisting of halo, C1-6 -alkylthio, C1-6 -alkylsulfonyl, cyano, nitro, C1-6 -haloalkyl, C1-6 -alkyl, hydroxyl, C2-6 -alkenyl, C1-6 -hydroxyalkyl, carboxyl, C3-6 -cycloalkyl, C1-6 -alkylamino, di -C1-6 -alkyl amino, C1-6 -alkoxycarbonyl, aminocarbonyl, C1-6 -alkoxy, C1-6 -haloalkoxy, sulfamyl, five or six membered heterocyclic and amino;
or a pharmaceutically-acceptable salt thereof;and one or more compounds selected from the group consisting of antibiotic agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon agents, miscellaneous agents, metallomatrix proteases (MMP) inhibitors, SOD and α
v β
3 inhibitors. - View Dependent Claims (13)
- wherein R5 is hydrido; and
Specification